object
studi
appli
pertin
find
gamma
inactiv
viru
infect
product
high
qualiti
diagnost
reagent
gammacel
atom
energi
canada
ltd
ottawa
canada
use
subject
virus
grown
either
suscept
tissu
cultur
embryon
chicken
egg
variou
dose
gamma
radiat
sourc
radiat
requir
reduc
viral
infect
megarad
mrad
effect
gamma
treatment
antigen
reactiv
reagent
complement
fixat
cf
hemagglutin
ha
neuraminadas
assay
determin
influenza
antigen
inactiv
mrad
display
compar
potenc
sensit
specif
stabil
inactiv
standard
procedur
betapropiolacton
bpl
signific
inactiv
influenza
nl
b
neuraminidas
occur
mrad
radiat
temperatur
virus
inactiv
cf
ha
antigen
prepar
success
antigen
potenc
remain
stabl
antigen
year
year
storag
influenza
ha
antigen
evalu
year
storag
demonstr
stabil
gamma
radiat
safer
chemic
inactiv
procedur
reliabl
effect
replac
bpl
prepar
diagnost
reagent
gamma
radiat
use
inactiv
human
anim
diagnost
biolog
product
method
describ
wide
rang
use
includ
steril
raw
cook
ground
beef
contain
coxsackieviru
steril
laboratori
effluent
releas
environ
larg
pool
anim
serum
use
tissu
cultur
medium
radiat
treat
inactiv
adventiti
virus
hyclon
laboratori
inc
logan
utah
usa
center
diseas
control
cdc
prepar
diagnost
refer
reagent
mani
viral
diseas
public
health
import
refer
reagent
suppli
state
counti
world
health
organ
laboratori
well
commerci
manufactur
diagnost
reagent
potenti
hazard
ship
infecti
materi
cdc
suppli
inactiv
reagent
histor
biolog
inactiv
treatment
correspond
address
use
trade
name
identif
impli
endors
public
health
servic
us
depart
health
human
servic
heat
ultraviolet
light
variou
chemic
includ
betapropiolacton
bpl
potenti
carcinogen
hazard
laboratorian
associ
use
deleteri
effect
bpl
hemagglutin
ha
antigen
laboratori
investig
inactiv
ofvir
reagent
gamma
radiat
sourc
gamma
radiat
offer
low
energi
nonpollut
method
kill
virus
control
condit
result
product
safe
radioact
inert
report
establish
dosag
level
requir
inactiv
treatment
viral
diagnost
reagent
discuss
longterm
stabil
reagent
gamma
radiat
sourc
gamma
radiat
sourc
gammacel
atom
energi
canada
ltd
ottawa
canada
contain
initi
activ
x
radh
megaradh
mrad
calcul
made
time
use
account
decay
cobalt
sourc
thirtyeight
refer
viru
strain
tabl
l
compris
genera
seven
famili
use
studi
viru
grown
host
system
give
maximum
sensit
infect
use
routin
reagent
product
virus
pass
laboratori
least
twice
use
inocula
reagent
prepar
six
cell
line
tabl
use
routin
cultur
system
produc
diagnost
reagent
virus
examin
cell
line
human
embryon
lung
hel
human
rhabdomyosarcoma
rd
rhesu
monkey
kidney
llcmka
primari
rhesu
monkey
kidney
prrhk
african
green
monkey
kidney
vero
african
green
monkey
kidney
cell
monolay
grown
either
cultur
flask
roller
bottl
growth
cell
monolay
confluent
growth
medium
remov
monolay
rins
serumfre
medium
viral
inoculum
ad
monolay
adsorb
cell
h
mainten
medium
tabl
ad
cultur
incub
harvest
maximum
cytopath
effect
cpe
observ
influenza
newcastl
diseas
virus
prepar
lodayold
embryon
chicken
egg
inocul
allanto
rout
eggah
influenza
type
c
viru
cultur
embryon
egg
inocul
amniot
rout
eggamn
egg
incub
h
appropri
fluid
harvest
overnight
refriger
standard
microtit
cf
develop
cdc
standard
hemagglutin
ha
hemagglutinationinhibit
hi
util
proper
erythrocyt
suspens
use
throughout
studi
inactiv
influenza
reagent
evalu
neuraminidas
inhibit
nd
test
cdc
inventoryil
refer
antigen
antisera
use
test
control
evalu
sensit
specif
radiationinactiv
reagent
pool
suspens
materi
infect
viru
prepar
aliquot
store
sampl
pool
suspens
thaw
radiat
experi
round
screwcap
glass
bottl
contain
approxim
ml
viru
suspens
place
gammacel
sampl
chamber
mechan
lower
posit
radiat
exposur
throughout
exposur
sampl
immers
crush
ice
kept
inactiv
experi
perform
time
interv
correspond
approxim
mrad
individu
sampl
remov
radiat
treatment
rang
mrad
sampl
held
assay
within
hour
residu
live
viru
infect
assay
untreat
treat
suspens
perform
inocul
viral
dilut
log
interv
host
system
use
antigen
product
three
screwcap
cell
cultur
tube
six
embryon
egg
inocul
per
dilut
cultur
incub
examin
daili
cpe
day
embryon
egg
incub
day
refriger
overnight
collect
allanto
amniot
fluid
hemagglutin
virus
ha
test
perform
fluid
individu
egg
cultur
tube
three
seven
day
incub
infect
titer
calcul
method
reed
muenchi
express
either
egg
infect
dose
eid
tissu
cultur
infect
dose
tcidso
confhut
inactiv
passag
fluid
appar
uninfect
cultur
dilut
infect
titrat
cell
cultur
frozen
thaw
pool
fluid
dilut
pool
passag
fluid
inocul
onto
suscept
host
examin
cpe
day
incub
inactiv
virus
cultur
embryon
egg
confirm
passag
pool
fluid
dilut
egg
incub
fluid
individu
egg
test
hemagglutinin
antigen
prepar
use
either
complement
fixat
cf
hemagglutinationinhibit
test
use
product
procedur
describ
biolog
product
procedur
manual
procedur
recommend
inactiv
use
bpl
howev
instead
bpl
experiment
reagent
inactiv
gammacel
radiat
level
calcul
inform
obtain
viru
inactiv
experi
volum
diagnost
reagent
ml
gamma
inactiv
procedur
ident
describ
innocu
confirm
antigen
potenc
determin
reagent
dispens
ml
aliquot
store
either
initi
experi
involv
weekli
test
influenza
reagent
longterm
stabil
test
antigen
potenc
sensit
expand
includ
cf
ha
reagent
store
either
gyear
period
preliminari
experi
conduct
determin
amount
gamma
radiat
requir
inactiv
infect
influenza
viru
strain
allanto
fluid
pool
ml
prepar
influenza
type
b
virus
amniot
fluid
pool
prepar
egg
infect
influenza
pool
dispens
ml
aliquot
glass
screwcap
bottl
expos
five
increas
amount
gamma
radiat
mrad
duplic
infect
titrat
perform
six
embryon
egg
per
dilut
untreat
treat
materi
incub
fluid
egg
harvest
individu
test
hemagglutinin
posit
ha
use
indic
infect
rate
inactiv
determin
reduct
infect
titer
tabl
anew
inactiv
mrad
smallest
radiat
dosag
requir
inactiv
influenza
virus
four
strain
inactiv
mrad
remain
eight
virus
noninfect
exposur
mrad
innocu
confirm
titrat
fluid
individu
egg
infect
endpoint
dilut
infect
titer
decreas
direct
proport
increas
radiat
qualiti
control
inactiv
antigen
bpl
use
treat
addit
sampl
influenza
pool
routin
procedur
pool
innocu
test
embryon
egg
noninfecti
treatment
bpl
stabil
untreat
versu
gammaand
bplinactiv
hemagglutinin
split
sampl
compar
tabl
gamma
bpl
concentr
use
previous
determin
effect
inactiv
influenza
antigen
compar
ha
titer
obtain
antigen
inactiv
procedur
except
show
fourfold
decreas
titer
follow
bpl
treatment
antigen
specif
determin
hi
test
refer
chicken
antisera
inactiv
antigen
inhibit
refer
homolog
antisera
titer
within
twofold
obtain
noninactiv
control
radiat
mrad
caus
chang
antigen
specif
antigen
perform
refer
reagent
unaffect
use
standard
neuraminidas
assay
percentag
neuraminidas
activ
remain
split
sampl
gamma
bpl
inactiv
compar
percentag
activ
infecti
control
prepar
neuraminidas
activ
control
inactiv
prepar
test
least
two
occas
tabl
five
bplinactiv
two
gammainactiv
influenza
prepar
show
higher
percentag
remain
neuraminidas
activ
correspond
inactiv
sampl
four
specimen
hznz
heql
neql
exhibit
varianc
sampl
amount
remain
neuraminidas
four
specimen
consid
compar
greater
stabil
nl
observ
bpl
inactiv
neql
neuraminadas
activ
stabl
inactiv
method
except
less
inactiv
observ
gamma
treatment
sinc
greater
inactiv
type
nl
b
neuraminidas
radiat
observ
addit
investig
perform
repeat
neuraminidas
assay
five
select
influenza
antigen
influenza
ainew
hswlnl
hlnl
bhong
reevalu
includ
low
result
previous
obtain
aequinemiami
use
control
antigen
expos
five
radiat
dose
mrad
three
temperatur
condit
unrefriger
c
ice
bath
c
frozen
fig
inactiv
infect
slower
frozen
state
requir
mrad
compar
mrad
temperatur
neuraminidas
inactiv
rate
increas
higher
temperatur
increas
amount
radiat
signific
inactiv
influenza
b
nl
neuraminidas
confirm
satisfactori
level
remain
treatment
occur
neuraminidas
level
show
less
inactiv
observ
previou
experi
howev
temperatur
c
signific
inactiv
occur
higher
radiat
level
evid
frozen
sampl
neuraminidas
control
demonstr
good
stabil
temperatur
second
group
virus
investig
contain
enteroviru
strain
object
determin
amount
gamma
radiat
requir
inactiv
virus
grown
cell
cultur
enterovirus
requir
mrad
inactiv
poliovirus
coxsackieviru
requir
mrad
enterovirus
inactiv
mrad
tabl
innocu
confirm
pool
suspens
endpoint
dilut
previous
describ
cpe
observ
day
incub
c
innocu
consid
confirm
six
differ
virus
three
enteroand
three
myxo
loday
embryon
egg
infect
titer
determin
pool
antigen
gammainactiv
chill
ice
bath
serolog
reactiv
compar
obtain
noninactiv
materi
tabl
innocu
test
perform
confirm
host
system
radiat
dosag
necessari
inactiv
vari
virus
inactiv
ha
titer
measl
newcastl
diseas
parainfluenza
type
remain
stabl
reoviru
type
show
fourto
eightfold
decreas
titer
retain
satisfactori
potenc
reoviru
type
ha
antigen
exhibit
eightfold
titer
declin
unsatisfactori
potenc
ha
titer
simian
rotaviru
total
destroy
compar
cf
titer
nonirradi
irradi
antigen
observ
two
antigen
coronaviru
respiratori
syncyti
show
twofold
decreas
potenc
gamma
treatment
three
antigen
prepar
parainfluenza
calf
simian
rotavirus
unsatisfactori
low
potenc
level
treat
nontreat
prepar
remain
cf
antigen
satisfactori
sensit
specif
inactiv
ha
cf
antigen
compar
cdc
refer
antigen
determin
test
homolog
heteroloof
seven
cf
antigen
maintain
titer
stabil
gou
cdc
refer
human
anim
antisera
byear
period
herpesviru
type
cf
interfer
anticomplementari
activ
antigen
show
fourfold
decreas
titer
still
observ
cf
antigen
maintain
accept
potenc
level
stabil
store
diagnost
reagent
thirteen
influenza
virus
repres
ha
alway
concern
reagent
manufactur
antigen
prepar
examin
period
examin
six
ha
seven
cf
gammainactiv
liquid
storag
period
year
antigen
held
routin
storag
condit
use
minimum
accept
influenza
approxim
year
ha
antigen
ha
antigen
titer
satisfactori
result
observ
measl
newcastl
diseas
parainfluenza
type
antigen
year
storag
reoviru
type
evalu
antigen
year
storag
studi
sought
ascertain
effect
gamma
radiat
potenc
sensit
viral
cf
ha
antigen
find
appli
product
high
qualiti
diagnost
reagent
initi
experi
involv
allanto
fluid
cultur
infect
differ
strain
influenza
viru
gamma
inactiv
procedur
compar
standard
techniqu
use
bpl
antigen
evalu
ha
hi
neuraminidas
assay
temperatur
radiat
definit
effect
stabil
influenza
viru
neuraminidas
ha
potenc
gammainactiv
antigen
compar
obtain
bplinactiv
antigen
determin
gammainactiv
influenza
ha
antigen
retain
potenc
specif
evalu
techniqu
prepar
cf
andor
ha
antigen
virus
virus
inactiv
gamma
radiat
mrad
without
advers
effect
potenc
sensit
specif
antigen
result
agre
efficaci
inactiv
viral
infect
gamma
radiat
depend
optim
radiat
exposur
radiat
requir
inactiv
vari
among
viru
group
report
thoma
et
inactiv
occur
along
predict
linear
lethal
dose
level
kinet
viru
inactiv
possibl
calcul
amount
radiat
requir
destroy
infect
still
retain
antigen
reagent
given
radiat
dosag
produc
incomplet
inactiv
suspens
subject
treatment
may
calcul
standard
inactiv
curv
gener
inactiv
viru
suspens
either
cell
cultur
allanto
fluid
gave
result
similar
noninactiv
prepar
cf
test
except
note
reoviru
simian
rotaviru
ha
antigen
inactiv
decreas
unaccept
level
fourfold
drop
observ
respiratori
syncyti
coronaviru
cf
antigen
inactiv
decreas
potenc
specif
three
antigen
suspens
cf
titer
antigen
alreadi
consid
accept
titer
number
year
cdc
viral
cf
ha
antigen
inactiv
gamma
radiat
evalu
stabil
influenza
ha
antigen
longterm
storag
report
tabl
result
includ
antigen
sever
influenza
strain
discuss
preliminari
experi
result
present
show
high
percentag
antigen
maintain
satisfactori
potenc
long
term
storag
laboratori
worker
consider
risk
infect
handl
larg
volum
infecti
viral
suspens
use
prepar
diagnost
reagent
also
face
exposur
hazard
chemic
includ
bpl
use
process
procedur
result
indic
gamma
radiat
effect
reliabl
inactiv
hightit
viru
suspens
without
affect
serolog
specif
procedur
safer
chemic
inactiv
effect
replac
bpl
prepar
inactiv
diagnost
reagent
